ClinicalTrials.gg
Not yet recruitingNCT07765160Updated Aug 14, 2026

Clinical Trials of IBI3040 in Healthy Participants and Overweight or Obese Participants

A Phase 1 interventional study of SAD: subcutaneous injection in the abdomen and MAD: subcutaneous injection in the abdomen in Healthy Participants and Overweight or Obese Participants, sponsored by Innovent Biologics (Suzhou) Co. Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-14.

Sponsored by Innovent Biologics (Suzhou) Co. Ltd. (part of Innovent Biologics, Inc.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
96
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 12 studies in Overweight by Innovent Biologics, Inc. — 5 open to participants now, 7 under way, 3 of them phase 3. Overweight · Innovent Biologics, Inc..

Planned enrollment
8th of 12
96 · median 116
Started
2026
with 3 others
Phase 1
6 of 12
3 open now
Registered
10th of 12
by date

Among the 12 studies in Overweight by Innovent Biologics, Inc., this one is the 8th largest by planned enrollment, is one of 4 that started in 2026, is one of 6 in phase 1, and was the 10th registered.

Overweight

3,620 studies on the registry are indexed under Overweight; 862 are open to participants now.

Browse Overweight studies →

Open to participants now

5 of the 12 studies in Overweight by Innovent Biologics, Inc. are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 535 Overweight studies recruiting now, 160 (30%) set no upper age limit and 347 (65%) stop at 75 or younger; 64 take children under 18; 205 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Overweight by Innovent Biologics, Inc., or all of them as a file.
02

Study summary

Clinical trials of IBI3040 with single-dose administration in healthy participants and multiple-dose administration in overweight or obese participants.

03

Conditions studied

  • Healthy Participants
  • Overweight or Obese Participants

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All participants in Part A (SAD) and Part B (MAD) must meet inclusion criteria 1-3:

  • 1.The age at the time of should be between 18 and 65 years old (including both values), and there is no gender restriction.
  • 2.Female participants who are fertile and male participants whose partners are fertile must agree to use the methods specified in the protocol during the study period and within 90 days after the last administration. The pregnancy test results of female participants with fertility before randomization must be negative. Female participants should not breastfeed. Male/female participants must be willing to avoid donating sperm/eggs during the study period and within 90 days after the last administration.
  • 3. Be able to understand the procedures and methods of this research, be willing to strictly follow the clinical trial protocol to complete this trial, and voluntarily sign the informed consent form.

Participants of Part A (SAD) also need to meet inclusion criteria 4-6:

  • 4. Participants who were determined by the researchers to be normal or abnormal based on the results of various examinations such as medical history, vital signs, physical examination, 12-lead , laboratory tests, infectious disease screening, chest X-ray, and abdominal color Doppler ultrasound, but were determined by the researchers to have no clinical significance.
  • 5. During screening, 20 kg/m ² ≤ \<28 kg/m ²;
  • 6. When screening, the standard weight should be ≥50 kg

Participants of Part B (MAD) also need to meet inclusion criteria 7-8:

  • 7. During screening, 24 kg/m2 ≤BMI ≤40 kg/m2;
  • 8. The standard weight change within 3 months prior to screening should be no more than 5kg (reported by the participants themselves).

Exclusion criteria

Exclusion Criteria:

All participants in Part A (SAD) and Part B (MAD) who meet any one of the exclusion criteria 1-17 cannot be included in the corresponding stage of the study:

  • 1.Participants may be allergic to any component of the drug, GLP-1 or Amylin receptor agonists (see Appendix 3 for details), or have used GLP-1 or Amylin receptor agonists within 3 months prior to screening;
  • 2. A history of diabetes, or a level of ≥6.5% during the screening period, or a fasting blood glucose level of ≥7.0 mmol/L;
  • 3. Previous history of thyroid C-cell carcinoma, multiple endocrine adenomatosis (MEN) 2A or 2B, or related family history, or calcitonin ≥20 ng/L at screening;
  • 4. A history of acute or chronic pancreatitis in the past, or amylase or lipase >1.5× (ULN) at the time of screening;
  • 5. >1.5×ULN during the screening period; Or aspartate aminotransferase >1.5×ULN; Or total >1.5×ULN;
  • 6. During the screening period, the surface antigen is positive, or the antibody is positive, or the syphilis helix specific antibody is positive, or the antibody is positive;
  • 7. Abnormal 12-lead (ECG) during the screening period and judged by the researcher as having clinical significance, or ECG >450 ms, or heart rate \<60 beats per minute or >100 beats per minute;
  • 8. Having a history of suicidal behavior, or being considered to have a significant suicide risk at present, or having a PHQ (Depression Screening Scale) score of ≥15 at the time of screening, or being classified as category 4 or 5 on the C-SSRS (Columbia Suicide Severity Scale) at the time of screening, or choosing "yes" in suicidal behavior or suicidal ideation;
  • 9. Use of prescription and over-the-counter drugs within 2 weeks before screening or within 5 half-lives (excluding topical eye/nasal drops and creams without systemic exposure risk);
  • 10. Have participated in any clinical trials of drugs (or within five half-lives) or medical devices within three months prior to screening, or plan to participate in clinical trials of other drugs or medical devices during the trial period;
  • 11. Those who consumed an average of more than 2 units of alcohol per day in the three months prior to screening (1 unit of alcohol ≈360 mL of beer with an alcohol content of 5% or 45 mL of spirits with an alcohol content of 40% or 150 mL of wine with an alcohol content of 12%), or those who were unable to quit drinking during the trial period, or those with a positive breath test for alcohol;
  • 12. Smoking more than 5 cigarettes per day within the 3 months prior to screening;
  • 13. Those who have a history of drug abuse within the five years prior to screening, or have used drugs within the three months prior to screening, or have a positive urine drug screening result;
  • 14. Blood donation and/or blood loss within 3 months prior to screening ≥450 mL, or having undergone bone marrow donation, blood transfusion or severe blood loss, or having hemoglobinopathy, hemolytic anemia, sickle cell anemia, or \<120 g/L (for men) or \<110 g/L (for women);
  • 15. Inability to tolerate venipuncture for blood collection or fainting at the sight of needles and blood;
  • 16. Those whose injection site assessment is considered abnormal by the researchers;
  • 17. The researcher believes that there are other factors that are not suitable for participating in this trial.

Participants in Part A (SAD) cannot be included in the study if they meet the following exclusion criteria:

- 18. During the screening period, the systolic blood pressure is less than 90mmHg or ≥140mmHg, or the diastolic blood pressure is less than 50 mmHg or ≥90mmHg, or the pulse rate is less than 60 beats per minute or >100 beats per minute.

Participants in Part B (MAD) who meet any one of the exclusion criteria 19-25 cannot be included in the study:

  • 19. The following diseases (including but not limited to gastrointestinal, kidney, liver, nervous, blood, endocrine, tumor, lung, immune, mental or cardiovascular and cerebrovascular diseases) with clinical findings indicating clinical significance within 12 months prior to screening;
  • 20. A history of life-threatening diseases (excluding basal cell skin cancer or squamous cell skin cancer) within the five years prior to screening;
  • 21. Previous researchers have considered gastric emptying abnormalities (for example, severe gastroparesis or gastric outlet obstruction), who have undergone gastric bypass (bariatric) surgery or restrictive bariatric surgery, or have been taking drugs that directly affect gastrointestinal motility for a long time;
  • 22. During the screening period, systolic blood pressure is less than 90 mmHg or ≥160mmHg, or diastolic blood pressure is less than 50 mmHg or ≥100mmHg, or pulse rate is less than 60 beats per minute or >100 beats per minute.
  • 23. For drugs that have been used or are currently being used within the three months prior to screening and may cause significant standard weight gain, including but not limited to: tricyclic antidepressants, psychotropic drugs or sedatives (such as imipramine, amitriptyline, mirtazapine, paroxetine, phenylhydrazine, chlorpromazine, thiridazine, clozapine, olanzapine, valproic acid, valproic acid derivatives, lithium salts);
  • 24. Having used weight-loss drugs or alternative therapies within the three months prior to screening, including but not limited to: GLP-1 or Amylin receptor agonists, orlistat, sibutramine hydrochloride, phenylpropanolamine, chlorphenimidole, butylamine, clocaserin hydrochloride, fentamine, fentamine/topiramate mixture, anferylene and naltrexone/bupropion mixture.
  • 25. Thyroid tumors or thyroid nodules with a Thyroid Imaging Reporting and Data System (TI-RADS) grade of ≥4 were present during screening.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
96 participants (estimated)

Study arms

  • Experimental
    IBI3040

    IBI3040, specification 0.6 ml:2.4 mg, injection, subcutaneous injection in the abdomen

    Drug: SAD: subcutaneous injection in the abdomen · Drug: MAD: subcutaneous injection in the abdomen

  • Active comparator
    IBI362

    IBI362, specifications: 0.5 ml:2 mg, 0.5 ml:4 mg and 0.5 ml:6 mg, injection, subcutaneous injection in the abdomen

    Drug: MAD: subcutaneous injection in the abdomen

  • Placebo comparator
    IBI3040 Placebo

    IBI3040 Placebo (without active ingredients), specification 0.6ml, injection, subcutaneous injection in the abdomen

    Drug: SAD: subcutaneous injection in the abdomen · Drug: MAD: subcutaneous injection in the abdomen

Interventions

  • DrugSAD: subcutaneous injection in the abdomen

    SAD: Single subcutaneous administration, with a safe follow-up period of 60 days

  • DrugMAD: subcutaneous injection in the abdomen

    MAD: Multiple administration, subcutaneous injection

06

What researchers measure

Primary outcomes

  1. SAD: The incidence rate of adverse events (AE)

    Time frame: through study completion, an average of 60 days

  2. SAD: The incidence rate of serious adverse events (SAE)

    Time frame: through study completion, an average of 60 days

  3. SAD: Number of subjects with clinically significant changes in physical examination results

    Time frame: through study completion, an average of 60 days

  4. SAD: Number of subjects with clinically significant changes in vital signs

    Vital signs including body temperature, pulse, respiratory rate and blood pressure

    Time frame: through study completion, an average of 60 days

  5. SAD: Number of participants with abnormal laboratory tests results

    laboratory tests including Blood routine、Blood Biochemistry (including blood lipids)、Coagulation routine、Urine routine、blood amylase、blood lipase、Pregnancy test、Calcitonin and Glycated hemoglobin (HbA1c)

    Time frame: through study completion, an average of 60 days

  6. SAD: Number of subjects with clinically significant changes in twelve-lead electrocardiogram

    Time frame: through study completion, an average of 60 days

  7. MAD: The incidence rate of adverse events (AE)

    Time frame: through study completion, an average of 20 weeks

  8. MAD: The incidence rate of serious adverse events (SAE)

    Time frame: through study completion, an average of 20 weeks

  9. MAD: Number of subjects with clinically significant changes in physical examination results

    Time frame: through study completion, an average of 20 weeks

  10. MAD: Number of subjects with clinically significant changes in vital signs

    Vital signs including body temperature, pulse, respiratory rate and blood pressure

    Time frame: through study completion, an average of 20 weeks

  11. MAD: Number of participants with abnormal laboratory tests results

    laboratory tests including Blood routine、Blood Biochemistry (including blood lipids)、Coagulation routine、Urine routine、blood amylase、blood lipase、Pregnancy test、Calcitonin and Glycated hemoglobin (HbA1c)

    Time frame: through study completion, an average of 20 weeks

  12. MAD: Number of subjects with clinically significant changes in twelve-lead electrocardiogram

    Time frame: through study completion, an average of 20 weeks

Secondary outcomes

  1. SAD: area under the curve (AUC)

    Time frame: through study completion, an average of 60 days

  2. SAD: maximum concentration (Cmax)

    Time frame: through study completion, an average of 60 days

  3. SAD: time to maximum concentration (Tmax)

    Time frame: through study completion, an average of 60 days

  4. SAD: clearance (CL/F)

    Time frame: through study completion, an average of 60 days

  5. SAD: apparent volume of distribution (V/F)

    Time frame: through study completion, an average of 60 days

  6. SAD: half-life (T1/2)

    Time frame: through study completion, an average of 60 days

  7. SAD: Anti-drug antibodies (ADA)

    Time frame: through study completion, an average of 60 days

  8. SAD: neutralizing antibodies (NAb)

    Time frame: through study completion, an average of 60 days

  9. MAD: area under the curve (AUC)

    Time frame: through study completion, an average of 20 weeks

  10. MAD: maximum concentration (Cmax)

    Time frame: through study completion, an average of 20 weeks

  11. MAD: time to maximum concentration (Tmax)

    Time frame: through study completion, an average of 20 weeks

  12. MAD: clearance (CL/F)

    Time frame: through study completion, an average of 20 weeks

  13. MAD: apparent volume of distribution (V/F)

    Time frame: through study completion, an average of 20 weeks

  14. MAD: half-life (T1/2)

    Time frame: through study completion, an average of 20 weeks

  15. MAD: Anti-drug antibodies (ADA)

    Time frame: through study completion, an average of 20 weeks

  16. MAD: neutralizing antibodies (NAb)

    Time frame: through study completion, an average of 20 weeks

  17. MAD: The change in body weight from baseline and the rate of change

    Time frame: through study completion, an average of 20 weeks

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2026; primary completion for Nov 2027, 14 months later.

Of 215 industry-sponsored phase 1 interventional studies under Overweight, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 14. This study's planned 14 months is above that.

Counting every sponsor, half of 234 studies reached it within 9 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 11, 2026
First posted
Aug 14, 2026
StartEst.
Aug 30, 2026
Primary completionEst.
Nov 10, 2027
CompletionEst.
Dec 10, 2027
Last update
Aug 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07765160
Responsible party
Sponsor
First posted
Aug 14, 2026
Start date
Aug 30, 2026 (estimated)
Primary completion
Nov 10, 2027 (estimated)
Completion
Dec 10, 2027 (estimated)
Last update
Aug 14, 2026

Study contacts

Shanyu Xu
Contact
shanyu.xu@innoventbio.com
+86-0512-69566088

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion